Correlation between Interleukin-6 (IL-6), High Sensitivity C-Reactive Protein (hsCRP), Endothelin-1 (ET-1), Asymmetric Dimethylarginine (ADMA) and Insulin Resistance (HOMA-IR) in Central Obese Men

Andri Hidayat, Andi Wijaya, Harun Alrasyid

Abstract


BACKGROUND: Many studies have shown that obesity was closely related to insulin resistance via several pathways such as inflammation, oxidative stress, lipolysis, and endothelial dysfunction. This study was carried out to observe the correlation between inflammation (IL-6 and hsCRP), lipolysis process (ET-1), and endothelial dysfunction (ADMA) and insulin resistance (HOMA-IR) in centrally obese men.

METHODS: This was a cross sectional study on 62 male subjects aged 30–60 years old with waist circumference (WC) >90 cm. IL-6, ET-1 and ADMA levels were measured using ELISA method, while hsCRP and insulin were measured using chemiluminescence method. All blood testings were conducted in Prodia Clinical Laboratory.

RESULTS: The results showed that WC was significantly correlated with hsCRP (r=0.294, p=0.022 ), ET-1 (r=0.257, p=0.047 ) and ADMA (r=0.338, p=0.009). We also found a significant correlation between hsCRP with HOMA-IR (r=0.324, p=0.021), ADMA with HOMA-IR (r=0.280, p=0.045), and IL-6 with hsCRP (r=0.437, p=0.003).

CONCLUSIONS: hsCRP and ADMA have significant correlation with HOMA-IR in centrally obese men. HOMA-IR significantly increases in subjects with ADMA above median and either IL-6 or hsCRP above median, as compared to those in the other groups. Inflammation and endothelial dysfunction are important causal pathways of insulin resistance state in centrally obese men.

KEYWORDS: obesity, IL-6, hsCRP, ET-1, ADMA, HOMA-IR


Full Text:

PDF

References


Departemen Kesehatan Republik Indonesia. Riset Kesehatan Dasar Nasional (RISKESDAS). Jakarta: Depkes RI; 2007.

Wellen KE, Hotamisligil GS. Inflammation, stress and diabetes. J Clin Invest. 2005; 115: 1111-9, CrossRef.

Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res. 2004; 12: 180-6, CrossRef.

Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27: 2276-83, CrossRef.

Thalmann TS, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res. 2007; 75: 690-701, CrossRef.

Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006; 113: 1888-904, CrossRef.

Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005; 288: H2031-41, CrossRef.

Eriksson AK, Harmelen V, Stenson BM, Astrom G, Wahlen K, Laurencikiene J, et al. Endothelin-1 stimulates human adipocyte lipolysis through the ETA receptor. Int J Obese. 2009; 33: 67-74, CrossRef.

Boden G. Free fatty acids as target for therapy. Curr Opin Endocrinol Diabet. 2004; 11: 258-63, CrossRef.

Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis, and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. Int J Obes Relat Metab Disord. 2002; 26: 754-64, PMID.

Harmelen Vv, Eriksson A, Åstro G. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes. 2008; 57: 378-86, CrossRef.

Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation. 2005; 111: 1448-54, CrossRef.

Hanley AJG, Williams K, Stern MP. Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diab Care. 2002; 25: 1177-84, CrossRef.

Kristiansen OP, Poulsen TM. Interleukin-6 and diabetes the good, the bad, or the indifferent? Diabetes. 2005; 54 (Suppl 2): S114-24, CrossRef.

Pradhan AD, Manson JE, Rifai N. C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327-34, CrossRef.

Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008; 88: 1379-406, CrossRef.

Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, Caidahl K, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007; 56: 1630-37, CrossRef.

Vazquez IN, Veledo SF, Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 2008; 57: 3211-21, CrossRef.

Madsen RK, Plomgaard P, Moller K, Mittendorfer B, Pebersen BK. Influence of TNF-alpha and IL-6 infusion on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab. 2006; 291: E108-14, CrossRef.

Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia. 2004; 47: 1135-42, CrossRef.

Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 2003; 52: 1904-09, CrossRef.

Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007; 56: 728-34, CrossRef.

Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000; 20: 2032-7, CrossRef.




DOI: https://doi.org/10.18585/inabj.v3i1.133

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute